The number of FDA programs relevant to rare disease and advanced therapies has expanded meaningfully over the past several years. Alongside legacy programs like Orphan Drug Designation, the Agency has introduced pilots and frameworks to provide a more structured way for sponsors to think through and implement novel development and evidence-generation strategies, particularly for ultra-rare, genetically defined, and heterogeneous conditions.
Below is the current landscape as of early 2026, followed by considerations on how to apply and stack these programs to support actual program execution.
1. Foundational FDA Rare Disease Incentives
These remain the foundation of most rare disease programs:
- Orphan Drug Designation (ODD)
- Provides tax credits, PDUFA fee waiver, and 7 years of exclusivity upon approval. For most rare disease programs, this is an early and expected component of regulatory planning, often introduced at a preclinical stage.
- Rare Pediatric Disease (RPD) Designation & Priority Review Voucher (PRV)
- When applicable, this can introduce significant strategic and financial value.
- Orphan Products Grants Program
- Offers non-dilutive funding to support clinical development. Particularly relevant for sponsors advancing into early clinical studies.
- FDA Natural History Studies Grants Program
- This grant aims to accelerate product development for rare diseases by collecting data on how they progress over time.
In practice:
These designations help establish early program viability, both financially and operationally, while securing a strong regulatory position.
2. Rare Disease Focused Pilots and Frameworks
This is a key area of recent FDA focus, particularly to address challenges unique to small populations and non-traditional evidence generation.
- Rare Disease Endpoint Advancement (RDEA) Pilot Program
- Designed to support development and alignment on novel or adapted endpoints. Entry is selective and requires a clear rationale for the proposed approach.
- START Pilot Program
- Provides a frequent, structured cadence of interaction with the FDA during clinical development, with the aim of enabling earlier, more iterative alignment.
- Rare Disease Evidence Principles (RDEP)
- A framework outlining how substantial evidence may be generated in ultra-rare diseases, where traditional trial designs may not be feasible.
- Plausible Mechanism Pathway
- Intended for individualized or genetically defined therapies. Emphasizes a well-supported biological rationale, supported by early clinical or translational evidence and confirmation of target engagement.
In practice:
These programs help define evidence generation strategies that will be considered acceptable for approval, particularly when conventional approaches are not viable.
3. Expedited Development Programs
These legacy programs, made up of designations and pathways, remain central to rare disease development and are frequently incorporated with mature data.
- Fast Track Designation
- Can be submitted with or at any time after the IND. While not always development-critical, it can be pursued early and may support program visibility and broader awareness.
- RMAT (Regenerative Medicine Advanced Therapy) Designation
- Relevant for cell and gene therapies, offering early and frequent engagement, intensive guidance, and collaboration with senior FDA reviewers.
- Breakthrough Therapy Designation (BTD)
- One of the hardest designations to obtain, BTD provides intensive guidance based on preliminary clinical evidence indicating potential for substantial improvement over available therapies.
- Accelerated Approval
- A pathway, rather than a designation, requires FDA discussion and alignment and allows approval based on surrogate or intermediate clinical endpoints, with confirmatory evidence expected post-approval.
- Priority Review
- Reduces FDA review time from 10 months to 6 months.
In practice:
These programs influence development timelines and the level of interaction with the FDA and are most effective when aligned with the dataset's maturity and the overall development plan.
4. Voucher and Priority Programs
These programs are more situational but can have a meaningful impact on timing and asset value.
- Rare Pediatric Disease Priority Review Voucher (RPD PRV)
- Tropical Disease PRV Program
- Material Threat Medical Countermeasure (MCM) PRV Program
- Commissioner’s National Priority Voucher (CNPV) Program
The CNPV program reflects a newer mechanism for prioritizing products aligned with national health priorities, offering the potential for significantly accelerated review.
In practice:
These programs are considered alongside submission strategy and broader corporate objectives.
5. Considerations For Layering Across Programs
When used together, these programs can be highly advantageous, both in advancing regulatory strategy and in strengthening how the program is positioned with stakeholders, when applied in a coordinated, layered way.
- Layer 1 – Foundational/baseline
- ODD, RPD, and grants establish early positioning and support.
- Layer 2 – Expedited Programs and those intended to increase engagement frequency
- Depending on program stage and data readiness, stacking such as Fast Track, Breakthrough, RMAT, or pilots, including START, and RDEA, can shape the pace of development and level of FDA interaction.
- Layer 3 – Evidence generation approach
- RDEP, Plausible Mechanism, and Accelerated Approval frameworks guide how data can be generated and interpreted in complex or constrained settings.
- Layer 4 – Review and approval timing
- Priority Review, PRVs, and CNPV influence review timelines and, in some cases, overall program value.
This structure allows sponsors to map regulatory strategy to the realities of their program stage, data, disease characteristics, and long-term objectives.
The FDA’s approach to rare diseases continues to evolve in a way that reflects the inherent challenges that come with developing drugs for small populations and the novel scientific advances:
- More flexibility in trial design and evidence generation
- Earlier and more iterative engagement opportunities
- Continued emphasis on demonstrating meaningful clinical benefit
For Sponsors, there is a great opportunity to use these designations, pilots, and pathways in a way that is coherent, intentional, and aligned with the Agency’s is current thinking.
For a view into how RareMoon supports sponsors as they navigate the designation landscape, explore our Regulatory Designation Action Plan service.